A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2-Reference-Cited by-同舟云学术

A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2

Published:2001-10 Issue:7 Volume:72 Page:1261-1267
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:Transplantation

Author:

Ponticelli Claudio,Yussim Alexander,Cambi Vincenzo,Legendre Christophe,Rizzo Gaetano,Salvadori Maurizio,Kahn Delawir,Kashi Habib,Salmela Kaija,Fricke Lutz,Heemann Uwe,Garcia-Martinez Javier,Lechler Robert,Prestele Hans,Girault Daniele

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference19 articles.

1. PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL ANTIBODY USED IN CADAVERIC RENAL TRANSPLANTATION

2. DISPOSITION OF BASILIXIMAB, AN INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY, IN RECIPIENTS OF MISMATCHED CADAVER RENAL ALLOGRAFTS1

3. REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2

4. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Induction Therapy on Antibody-Mediated Rejection in Kidney Transplantation: A Network Meta-Analysis Using Recent Data;Transplantation Proceedings;2024-04

2. Hospitalizations after Renal Transplantation in Children: Risk Factors, Causes, and Outcomes;Nephron;2023-11-02

3. Use and Outcomes of Induction Therapy in Well-Matched Kidney Transplant Recipients;Clinical Journal of the American Society of Nephrology;2022-02

4. Invasive Fungal Disease;Infectious Complications in Biologic and Targeted Therapies;2022

5. Immunosuppression and Solid Organ Transplantation;Atlas of Dermatologic Diseases in Solid Organ Transplant Recipients;2022